On February 11, the FDA authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply: They have a positive COVID-19 test resultThey’re at high-risk for progression to severe COVID-19Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically...Read More